PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Total Current Liabilities

All obligations due within one year.

PepGen Inc.NASDAQ: PEPG

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities falls 56.1% from a year ago

Total current liabilities stood at $8.96M at the end of Q1 FY2026, down 56.1% from a year earlier and down 29.1% from the prior quarter. Over 3 fiscal years it compounded at -12.4% a year.

Context

  • Total current liabilities amounted to 5.7% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
  • Total current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -56.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.96M-29.1% QoQ
Last fiscal yearDec 2025
$12.65M-24.3% YoY
Year agoMar 2025
$20.43M-56.1% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.1%——
1 year-24.3%——
3-year CAGR-12.4%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
12.65M USD
Year-over-year change
-24.3%
4-year CAGR
+5.2%

Total Current Liabilities vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -56.1% is the 7th highest of 8, against a peer median of -2.1%.
  • Total current liabilities amounts to 5.7% of total assets for PEPG, versus a peer median of 12.6%.
PEPG Competitors
Total Current Liabilities for PEPG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALECAlector, Inc.Mar 2026$40.97M USD-62.7%-9.5%17.1%
FATEFate Therapeutics, Inc.Mar 2026$30.69M USD+9.0%-31.9%10.8%
NKTXNkarta, Inc.Mar 2026$18.21M USD-2.9%+0.3%4.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$18.14M USD+56.1%+17.9%12.6%
CRDFCardiff Oncology, Inc.Mar 2026$14.46M USD+8.8%+28.1%29.4%
PEPGPepGen Inc.Mar 2026$8.96M USD-56.1%-12.4%5.7%
MOLNMolecular Partners AGMar 2026CHF 8.77M CHF-2.1%-13.9%10.0%
ELTXElicio Therapeutics, Inc.Mar 2026$7.23M USD-36.7%+5.7%31.9%
Peer median (excluding PEPG) —-2.1%+0.3%12.6%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.9M181.75M80.77M49.42M60.51M
Short-term Investments0029.63M70.77M87.94M
Net Receivables4.74M58K000
Inventory00000
Other Current Assets04.27M2.27M3.57M2.51M
Total Current Assets139.99M186.08M112.68M123.76M150.96M
Property, Plant & Equipment (Net)636K29.88M28.38M25.15M21.02M
Goodwill00000
Intangible Assets00000
Long-term Investments1.47M0000
Tax Assets00000
Other Non-current Assets1.55M1.47M1.99M1.97M1.92M
Total Non-current Assets3.66M31.36M30.37M27.12M22.94M
Total Assets143.64M217.44M143.05M150.88M173.91M
Account Payables3.24M1.36M1.01M1.75M822K
Short-term Debt00000
Tax Payables02.57M000
Deferred Revenue00000
Other Current Liabilities1.21M2.44M2.37M3.62M4.66M
Total Current Liabilities10.32M18.83M17.53M16.7M12.65M
Long-term Debt000013.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226K0000
Total Non-current Liabilities226K18.98M17.1M15.57M13.82M
Total Liabilities10.55M37.81M34.63M32.26M26.46M
Common Stock02K2K3K7K
Retained Earnings(33.75M)(102.86M)(181.48M)(271.46M)(361.12M)
Accumulated OCI17K(81K)34K23K11K
Other Stockholders Equity00000
Minority Interest00000
Total Equity133.09M179.63M108.42M118.62M147.44M
Total Debt024.53M20.1M18.66M17M
Net Debt(132.9M)(157.22M)(60.67M)(30.76M)(43.51M)

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.